They Don't call "Motley" a "Fool" for Nothing. . . .

As Brian Orelli proved, once again
today, with his incoherent take
on the FDA and Congressional interest
in the Vytorin SEAS data on cancer.

Meanwhile, in the real world,
here's some more on the FDA
advance notification -- and more on
the Congressional request.

Yep -- "a fool is, as a fool does. . . ."